Video

Dr Monga on the Investigation of PRT811 in High-Grade Glioma or Uveal Melanoma

Author(s):

Varun Monga, MD, discusses the investigation of the protein arginine methyltransferase 5 brain-penetrant inhibitor PRT811 in patients with recurrent high-grade glioma or uveal melanoma.

Varun Monga, MD, clinical associate professor, Internal Medicine, Hematology, Oncology, and Blood and Marrow Transplantation, University of Iowa, discusses the investigation of the protein arginine methyltransferase 5 (PRMT5) brain-penetrant inhibitor PRT811 in patients with recurrent high-grade glioma or uveal melanoma.

A phase 1 trial (NCT04089449) investigated PRT811 monotherapy in patients with advanced solid tumors, central nervous system lymphoma, or glioma. Data from cohorts of patients with high-grade glioma (n = 38) and uveal melanoma (n = 23) who enrolled in the expansion phase of the trial and received the recommended phase 2 dose of 600 mg of oral PRT811 per day, Monga says. Safety findings were consistent with previous data from the dose-escalation portion of the study, he says. The majority of treatment-emergent adverse effects were grade 1 or 2, and they included gastrointestinal toxicities, fatigue, fall, and myelosuppression.

Efficacy was evaluated by IDH mutation status within the glioma cohort by splicing mutation status in the uveal melanoma cohort, Monga explains.

The overall response (ORR) rate in patients with IDH-positive glioma (n = 16) was 12.5%, with both responders experiencing a complete response. However, no patients responded in the IDH-negative group (n = 22). Those with uveal melanoma group with splicing mutations (n = 10) had an ORR of 10%, with 1 patient achieving a partial response. No patients responded in the group of patients without splicing mutations (n = 13). he expands.

The clinical benefit rate (CBR) was 31.3% for the IDH-mutated glioma population, and it was 4.5% for the IDH-unmutated population. In patients with uveal melanoma, the CBR was 30.0% and 7.7% for the splicing mutation–positive and –negative populations, respectively.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity